Previous Close | 4.55 |
Open | 4.54 |
Bid | 4.60 x 300 |
Ask | 4.84 x 300 |
Day's Range | 4.53 - 4.85 |
52 Week Range | 0.88 - 7.36 |
Volume | 934,483 |
Avg. Volume | 1,395,187 |
Market Cap | 239.895M |
Beta | 2.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.79 |
Earnings Date | May 8, 2018 - May 14, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.13 |
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
In December 2017, Viking Therapeutics Inc (NASDAQ:VKTX) announced its most recent earnings update, which revealed that losses became smaller relative to the prrior year’s level as a result of recentRead More...
Viking's shares finally cooled off last month, but that doesn't make them a buy.
Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. VK5211, which is being developed for acute rehabilitation following non-elective hip fracture surgery. • The company announced positive topline data from a Phase 2 trial in Nov. 2017 and we anticipate the full data set being presented at a scientific conference in the second half of 2018.
The biopharma released full-year 2017 earnings yesterday after the market closed.
Conference call scheduled for 4:30 p.m. ET today - VK5211 Phase 2 trial in hip fracture achieves primary and multiple secondary endpoints - VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding, ...
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Viking Therapeutics, Inc. (NASDAQ: VKTX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern ...
SAN DIEGO , March 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Industrial metals and infrastructure plays highlight March's penny stock list, with Congress set to increase spending on roads, bridges and tunnels.
Conference Call Scheduled for Wednesday, March 7 at 4:30 p.m. Eastern Time SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great ...
I am going to take a deep dive into Viking Therapeutics Inc’s (NASDAQ:VKTX) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...
- Healthcare Stocks Ripping Higher Amid Acquisitions and Expectations for More in 2018. Cardio Monitoring Companies like IRTC and BEAT have been Great Performers as They Penetrate Huge Market - Upstart ...
SAN DIEGO , Feb. 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock jump more than 15%. What is magnetizing investors to invest in Viking Therapeutics Inc (NASDAQ:VKTX) today? The pricing of a public offering- as Viking ties up an equity financing, it is pricing its public offering of common stock to bring $55 million to its table.
SAN DIEGO, Feb. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 11,000,000 shares of its common stock at a price to the public of $5.00 per share. Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. William Blair & Company, L.L.C. is acting as sole book-running manager for the offering and Maxim Group LLC and Roth Capital Partners are acting as co-managers for the offering.
SAN DIEGO, Feb. 1, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Viking.
If you are a shareholder in Viking Therapeutics Inc’s (NASDAQ:VKTX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
Interest and volume in the stock picked up in September and continues to build.
Viking Therapeutics, Inc. (VKTX) is currently testing VK2809, the company’s thyroid hormone receptor beta (TRβ) agonist, in a Phase 2 clinical trial in patients with hypercholesterolemia and fatty liver disease. The company is enrolling patients with elevated cholesterol and fatty liver disease, as assessed by liver fat content ≥ 8% by MRI-PDFF. The primary endpoint will assess changes in LDL cholesterol following 12 weeks of treatment, with exploratory endpoints evaluating changes in liver fat content, inflammatory markers, and histological changes.
SAN DIEGO , Jan. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Viking Therapeutics Inc’s (NASDAQ:VKTX) released its most recent earnings update in September 2017, which revealed that losses became smaller relative to the prrior year’s level – great news for investorsRead More...
Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP’s corporate tax cut plans.